RBC Capital Markets has updated its coverage of Johnson & Johnson (JNJ), maintaining an "Outperform" rating while raising its 12-month price target to US$290 per share. The company's second-quarter 2026 results showed strong performance, with sales reaching US$25.3 billion, a 6.6% increase, and adjusted earnings per share (EPS) of US$2.90. JNJ also raised its full-year outlook, projecting a reported-sales midpoint of US$101.1 billion and an adjusted-EPS midpoint of US$11.68.
The investment case for Johnson & Johnson hinges on sustained growth in innovative medicines and medical technology. New products must generate enough earnings to counterbalance competitive pressures on existing treatments. For investors, sales growth is most valuable when it supports long-term profit and cash generation.
Valuation risks include slower product adoption, pricing pressures, patent competition, or adverse legal outcomes. A premium valuation requires confidence that earnings will remain resilient beyond the current forecast year. Analysts have a cautiously positive outlook, with a "Buy" consensus rating and a 12-month price target of US$280, suggesting a 10% upside. However, a "Strong Sell" technical signal indicates near-term weakness, creating a divide between analysts' optimism and current market momentum.